Citigroup Inc. Raises Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Citigroup Inc. boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,042,574 shares of the medical equipment provider’s stock after buying an additional 38,362 shares during the quarter. Citigroup Inc.’s holdings in Hologic were worth $84,928,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Bessemer Group Inc. boosted its holdings in shares of Hologic by 8.0% during the first quarter. Bessemer Group Inc. now owns 10,892 shares of the medical equipment provider’s stock worth $848,000 after purchasing an additional 809 shares during the period. Canada Pension Plan Investment Board lifted its holdings in Hologic by 72.6% in the 1st quarter. Canada Pension Plan Investment Board now owns 453,913 shares of the medical equipment provider’s stock worth $35,387,000 after buying an additional 190,881 shares during the period. 1832 Asset Management L.P. grew its position in shares of Hologic by 6.2% in the 1st quarter. 1832 Asset Management L.P. now owns 27,417 shares of the medical equipment provider’s stock worth $2,137,000 after buying an additional 1,597 shares during the last quarter. BOKF NA raised its holdings in shares of Hologic by 6.4% during the first quarter. BOKF NA now owns 10,508 shares of the medical equipment provider’s stock valued at $800,000 after acquiring an additional 631 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after acquiring an additional 2,753,016 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on HOLX shares. Leerink Partners cut their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Stephens reiterated an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. Mizuho dropped their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Royal Bank of Canada upped their price objective on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Finally, StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic has an average rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Stock Performance

HOLX stock opened at $78.97 on Friday. The stock has a market capitalization of $18.34 billion, a PE ratio of 23.71, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98. The stock’s 50 day simple moving average is $80.44 and its 200 day simple moving average is $78.32. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same period last year, the firm posted $0.89 earnings per share. Hologic’s revenue was up 4.5% compared to the same quarter last year. As a group, research analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.